Literature DB >> 28546279

Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism.

Raffaele Pesavento1, Lucia Filippi2, Antonio Palla3, Adriana Visonà4, Carlo Bova5, Marco Marzolo6, Fernando Porro7, Sabina Villalta8, Maurizio Ciammaichella9, Eugenio Bucherini10, Giovanni Nante2, Sandra Battistelli11, Maria Lorenza Muiesan12, Giampietro Beltramello13, Domenico Prisco14, Franco Casazza15, Walter Ageno16, Gualtiero Palareti17, Roberto Quintavalla18, Simonetta Monti19, Nicola Mumoli20, Nello Zanatta21, Roberto Cappelli22, Marco Cattaneo23, Valentino Moretti24, Francesco Corà25, Mario Bazzan26, Angelo Ghirarduzzi27, Anna Chiara Frigo28, Massimo Miniati14, Paolo Prandoni28.   

Abstract

The impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months and then were followed up for up to 3 years. Recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension were assessed according to widely accepted criteria.Residual pulmonary obstruction was detected in 324 patients (50.1%, 95% CI 46.2-54.0%). Patients with residual pulmonary obstruction were more likely to be older and to have an unprovoked episode. After a 3-year follow-up, recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension developed in 34 out of the 324 patients (10.5%) with residual pulmonary obstruction and in 15 out of the 323 patients (4.6%) without residual pulmonary obstruction, leading to an adjusted hazard ratio of 2.26 (95% CI 1.23-4.16).Residual pulmonary obstruction, as detected with perfusion lung scanning at 6 months after a first episode of pulmonary embolism, is an independent predictor of recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28546279     DOI: 10.1183/13993003.01980-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  The Post-Pulmonary Embolism Syndrome: Real or Ruse?

Authors:  Steven C Pugliese; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2019-07

2.  Residual pulmonary hypertension is associated with clinical outcomes in patients with acute pulmonary thromboembolism.

Authors:  Tatsuro Ibe; Hiroshi Wada; Kenichi Sakakura; Seiichiro Yoshimura; Miyuki Ito; Yusuke Ugata; Kei Yamamoto; Masaru Seguchi; Yousuke Taniguchi; Shin-Ichi Momomura; Hideo Fujita
Journal:  Heart Vessels       Date:  2019-05-02       Impact factor: 2.037

3.  Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.

Authors:  Ming Sheng Lim; Dee Nandurkar; Ian Jong; Anita Cummins; Huyen Tran; Sanjeev Chunilal
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

4.  Impact of dedicated outpatient pulmonary follow-up for hospitalized patients with acute pulmonary embolism.

Authors:  Joseph G Noto; Parth Rali
Journal:  Pulm Circ       Date:  2022-01-20       Impact factor: 2.886

5.  Catheter-based interventions versus medical and surgical approaches in acute pulmonary embolism.

Authors:  Rafael S Cires-Drouet; Khanjan Nagarsheth; David J Kaczorowski; Shahab Toursavadkohi; Kristopher Deatrick; Ronson J Madathil; Kevin M Jones; Steven Liskov; Jeffrey Fitch; Michelle Sayad; Chetan Pasrija; Minerva Mayorga-Carlin; Daniel Herr; John D Sorkin; Bartley Griffith; Brajesh K Lal; James S Gammie
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2021-05-07

Review 6.  Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.

Authors:  Hannah Stevens; Karlheinz Peter; Huyen Tran; James McFadyen
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

7.  Quality of life and functional limitations after pulmonary embolism and its prognostic relevance.

Authors:  Karsten Keller; Clara Tesche; Aslihan Gerhold-Ay; Stefan Nickels; Frederikus A Klok; Lisa Rappold; Gerd Hasenfuß; Claudia Dellas; Stavros V Konstantinides; Mareike Lankeit
Journal:  J Thromb Haemost       Date:  2019-08-13       Impact factor: 5.824

8.  Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus.

Authors:  Daniel Lachant; Christina Bach; Bennett Wilson; Vaseem Chengazi; Bruce Goldman; Neil Lachant; Anthony Pietropaoli; Scott Cameron; R James White
Journal:  Pulm Circ       Date:  2020-09-21       Impact factor: 2.886

9.  Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.

Authors:  Benjamin Planquette; Olivier Sanchez; James J Marsh; Peter G Chiles; Joseph Emmerich; Grégoire Le Gal; Guy Meyer; Tanya Wolfson; Anthony C Gamst; Roger E Moore; Gabriel B Gugiu; Timothy A Morris
Journal:  Eur Respir J       Date:  2018-11-15       Impact factor: 33.795

Review 10.  Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19.

Authors:  Ranju T Dhawan; Deepa Gopalan; Luke Howard; Angelito Vicente; Mirae Park; Kavina Manalan; Ingrid Wallner; Peter Marsden; Surendra Dave; Howard Branley; Georgina Russell; Nishanth Dharmarajah; Onn M Kon
Journal:  Lancet Respir Med       Date:  2020-11-17       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.